Targeted Molecular Construct for Bioorthogonal Theranostics of PD- L1-Expressing Cancer Cells

Shiao Chow, Asier Unciti-Broceta*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Molecular targeting of tumor-overexpressed oncoproteins can improve the selectivity and tolerability of anticancer therapies. The immunoinhibitory membrane protein Programmed Death Ligand 1 (PD-L1) is highly expressed on certain tumor types, which masks malignant cells from T cell recognition and creates an optimal environment for the cancer to thrive and spread. We report here a ligand-tetrazine conjugate (LTzC) armed with a PD-L1 small molecule inhibitor to selectively target PD-L1-expressing cancer cells and inhibit PD-L1 function, and conjugated to a tetrazine module and a lipoyl group to incorporate bioorthogonal reactivities and an oxidative stress enhancer into the construct. By pairing LTzC with an imaging probe, we have established a ‘track-&-tag’ system for selective labeling of PD-L1 both on and in living cells using click chemistry. We have further shown the specificity and versatility of the LTzC by click-to-release activation of prodrugs and selective killing of PD-L1 expressing breast cancer cells, offering a new multimodal approach to ‘track-&-treat’ malignant cells that are capable of evading the immune system.
Original languageEnglish
Pages (from-to)1747-1756
JournalJACS Au
Volume2
Issue number7
DOIs
Publication statusPublished - 1 Jul 2022

Keywords / Materials (for Non-textual outputs)

  • Bioorthogonal
  • IEDDDA
  • Cycloaddition
  • Tumor Targeting
  • Tumor Labeling
  • Targeted Chemotherapy

Fingerprint

Dive into the research topics of 'Targeted Molecular Construct for Bioorthogonal Theranostics of PD- L1-Expressing Cancer Cells'. Together they form a unique fingerprint.

Cite this